THX PHARMA SACA (ALTHX.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALTHX • FR0013286259

2.14 EUR
-0.14 (-6.14%)
Last: Feb 6, 2026, 07:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to ALTHX. ALTHX was compared to 55 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ALTHX have multiple concerns. ALTHX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year ALTHX has reported negative net income.
  • In the past year ALTHX has reported a negative cash flow from operations.
  • ALTHX had negative earnings in each of the past 5 years.
  • In the past 5 years ALTHX always reported negative operating cash flow.
ALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFALTHX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • The Return On Assets of ALTHX (-64.91%) is worse than 87.27% of its industry peers.
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROIC N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTHX.PA Yearly ROA, ROE, ROICALTHX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

  • ALTHX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTHX.PA Yearly Profit, Operating, Gross MarginsALTHX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ALTHX has been increased compared to 1 year ago.
  • ALTHX has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALTHX is higher compared to a year ago.
ALTHX.PA Yearly Shares OutstandingALTHX.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALTHX.PA Yearly Total Debt VS Total AssetsALTHX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • ALTHX has an Altman-Z score of -0.42. This is a bad value and indicates that ALTHX is not financially healthy and even has some risk of bankruptcy.
  • ALTHX has a Altman-Z score of -0.42. This is in the lower half of the industry: ALTHX underperforms 78.18% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.42
ROIC/WACCN/A
WACCN/A
ALTHX.PA Yearly LT Debt VS Equity VS FCFALTHX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 0.93 indicates that ALTHX may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.93, ALTHX is doing worse than 80.00% of the companies in the same industry.
  • ALTHX has a Quick Ratio of 0.93. This is a bad value and indicates that ALTHX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ALTHX (0.93) is worse than 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
ALTHX.PA Yearly Current Assets VS Current LiabilitesALTHX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ALTHX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.71%.
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 69.31% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.33%
EPS Next 2Y69.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALTHX.PA Yearly Revenue VS EstimatesALTHX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2021 5M 10M 15M
ALTHX.PA Yearly EPS VS EstimatesALTHX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • ALTHX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALTHX is valuated rather expensively with a Price/Forward Earnings ratio of 20.78.
  • 60.00% of the companies in the same industry are cheaper than ALTHX, based on the Price/Forward Earnings ratio.
  • ALTHX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.78.
Industry RankSector Rank
PE N/A
Fwd PE 20.78
ALTHX.PA Price Earnings VS Forward Price EarningsALTHX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTHX.PA Per share dataALTHX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

  • ALTHX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • ALTHX's earnings are expected to grow with 69.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.31%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALTHX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

THX PHARMA SACA

EPA:ALTHX (2/6/2026, 7:00:00 PM)

2.14

-0.14 (-6.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-25
Earnings (Next)N/A
Inst Owners8.48%
Inst Owner ChangeN/A
Ins Owners10.12%
Ins Owner ChangeN/A
Market Cap29.53M
Revenue(TTM)N/A
Net Income(TTM)-2.94M
Analysts86.67
Price Target4.49 (109.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.52%
PT rev (3m)-0.52%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.45%
EPS NY rev (3m)-122.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.78
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.1
Fwd EY4.81%
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS-0.14
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.91%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.38%
ROA(5y)-54.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 172.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z -0.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.38%
Cap/Depr(5y)30.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1140%
EPS Next Y13.33%
EPS Next 2Y69.31%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.22%
OCF growth 3YN/A
OCF growth 5YN/A

THX PHARMA SACA / ALTHX.PA FAQ

What is the ChartMill fundamental rating of THX PHARMA SACA (ALTHX.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA.


Can you provide the valuation status for THX PHARMA SACA?

ChartMill assigns a valuation rating of 2 / 10 to THX PHARMA SACA (ALTHX.PA). This can be considered as Overvalued.


How profitable is THX PHARMA SACA (ALTHX.PA) stock?

THX PHARMA SACA (ALTHX.PA) has a profitability rating of 0 / 10.